CD163 and neoplasm: This scenario highlights the fact that in the presence of a CD163+ population with such a direct negative effect on anti-tumor immune cells, treatment via the activation of effector cells would be difficult without either depleting CD163+ cells or reprogramming their immunosuppressive functions.